Novo Nordisk's Wegovy and Eli Lilly's Zepbound deemed cost-effective for obesity management, but may break drug budgets.

ICER's Draft Evidence Report on Novo Nordisk's Wegovy and Eli Lilly's Zepbound found that the drugs are cost-effective when added to lifestyle modification, reducing metabolic risk factors and obesity-related health complications. However, the report also flagged concerns about affordability, as fewer than 1% of eligible patients can be treated before the drugs cross their budget impact threshold of $880 million annually.

The Institute for Clinical and Economic Review (ICER) has released a draft evidence report evaluating the comparative clinical effectiveness and value of Novo Nordisk's semaglutide (Wegovy) and Eli Lilly's tirzepatide (Zepbound) for obesity management. The report, released on September 9, 2025, finds that both drugs are cost-effective when used in conjunction with lifestyle modifications, offering substantial health benefits compared to lifestyle changes alone Pricing group says weight-loss drugs becoming more cost- ...^[1].

Cost-Effectiveness and Health Benefits

ICER's analysis determined that semaglutide and tirzepatide provide significant weight loss and improvement in metabolic risk factors, leading to substantial net health benefits over lifestyle modifications alone. The report highlighted that the drugs reduce the risk of obesity-related health complications, such as type 2 diabetes and cardiovascular diseases Pricing group says weight-loss drugs becoming more cost- ...^[1].

The report noted that although both drugs increase intervention costs, they yield long-term savings in non-intervention costs. The incremental cost-effectiveness ratios for semaglutide and tirzepatide were below commonly used cost-effectiveness thresholds, indicating that the drugs offer good value for money Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets^[2].

Affordability Concerns

Despite the positive cost-effectiveness findings, ICER flagged serious concerns about affordability. The report noted that fewer than 1% of eligible patients can be treated before the drugs cross their budget impact threshold of $880 million annually Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets^[2]. This highlights the significant financial burden that these drugs may impose on healthcare systems and payers.

Market Dynamics and Pipeline Innovations

The market for GLP-1 receptor agonists, which includes semaglutide and tirzepatide, has seen a shift in leadership. Eli Lilly's tirzepatide has overtaken Novo Nordisk's semaglutide in the U.S. obesity market share, driven by superior weight loss efficacy in clinical trials The GLP-1 Showdown: Eli Lilly's Surge Challenges Novo Nordisk's Diabetes and Obesity Dominance^[3]. Lilly's pipeline innovations, including an oral GLP-1 drug (orforglipron) and a next-generation injectable (retatrutide), outpace Novo's underperforming CagriSema and lack of format diversity The GLP-1 Showdown: Eli Lilly's Surge Challenges Novo Nordisk's Diabetes and Obesity Dominance^[3].

Conclusion

ICER's draft evidence report underscores the cost-effectiveness of semaglutide and tirzepatide when used in conjunction with lifestyle modifications. However, the report also highlights significant affordability concerns, which may limit access to these potentially beneficial treatments. As the market for obesity and diabetes therapeutics continues to evolve, addressing these affordability issues will be crucial for ensuring that patients can access these life-changing therapies.